MUSTANG BIO, INC. Sale of Stock, Consideration Received on Transaction
MUSTANG BIO, INC. (MBIO) reported Sale of Stock, Consideration Received on Transaction of $14.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-03-19
- MUSTANG BIO, INC. sale of stock, consideration received on transaction for fiscal 2025 was $14.50M, a 29.46% increase from fiscal 2024.
- MUSTANG BIO, INC. sale of stock, consideration received on transaction for fiscal 2024 was $11.20M.
| Period end | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|
| 2025-12-31 | $14.50M 10-K · filed 2026-03-19 |
| 2024-12-31 | $11.20M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |